NervGen to Host Inaugural R&D Day on September 30, 2026

NervGen will hold a webcast R&D Day to review NVG-291 data, SCI program rationale and its Phase 3 RESTORE trial design.

Rhea-AI Summary

NervGen (NGEN) will host its inaugural R&D Day webcast on Wednesday, September 30, 2026, from 10:00 a.m. to 12:00 p.m. ET.

The event will provide an in-depth review of NVG-291, covering its scientific rationale, nonclinical and translational evidence in spinal cord injury (SCI), broader therapeutic potential, clinical data from the Phase 1 program and Phase 1b/2a CONNECT SCI study in chronic cervical SCI, and the design and rationale of the Phase 3 RESTORE registrational study. Four external experts in SCI clinical care, outcome assessment, translational research and community advocacy will join NervGen management for presentations and a live Q&A, with a webcast and replay available via the company’s website.

Key Terms

phase 3, phase 1b/2a, patient-focused drug development, chondroitin sulfate proteoglycans

4 terms

phase 3 medical

"and the design and rationale of RESTORE, the Company’s Phase 3 registrational study."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 1b/2a medical

"Phase 1 program and Phase 1b/2a CONNECT SCI study"

Phase 1b/2a is a combined early-stage clinical study that first tests safety and optimal dosing in a small group and then expands to look for initial signs that the drug works in the target patients. Think of it as a prototype test followed by a small pilot run: it helps companies decide whether to invest in larger, more expensive trials. Investors watch these results because they reduce scientific uncertainty and can sharply affect a drug’s value and development timeline.

patient-focused drug development regulatory

"establish an SCI-focused Patient-Focused Drug Development (PFDD) meeting"

Patient-focused drug development is the practice of incorporating patients’ experiences, needs and priorities into how medicines are designed, tested and evaluated—like using customer feedback to shape a new product. For investors it matters because drugs that address real patient problems and demonstrate meaningful benefits are more likely to win regulatory support, achieve higher uptake and command stronger pricing, reducing development risk and improving potential returns.

chondroitin sulfate proteoglycans medical

"enzymatic degradation of chondroitin sulfate proteoglycans (CSPGs)"

Molecules made of a protein core with long sugar chains called chondroitin sulfate attached, found in the extracellular matrix around cells. They act like biological scaffolding and sticky glue that influence cell growth, movement, tissue repair and nerve regeneration; that role makes them potential drug targets or biomarkers in development programs and affects how some therapies work.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• R&D Day to feature an in-depth review of NVG-291, including its nonclinical and translational foundation, broader therapeutic potential, clinical data generated to date, perspectives from the SCI community, and the Phase 3 RESTORE study design and rationale
• Four leading experts spanning spinal cord injury clinical care, outcome assessment, translational research and community advocacy to join NervGen management for presentations and a live question-and-answer session
• Live webcast on Wednesday, September 30, 2026, beginning at 10:00 a.m. ET
  

VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that it will host its inaugural R&D Day webcast on Wednesday, September 30, 2026, from 10:00 a.m. to 12:00 p.m. ET.

The event will provide an in-depth review of the NVG-291 program, spanning the scientific rationale and breadth of nonclinical and translational evidence supporting its development in SCI while highlighting the broader therapeutic potential; clinical data from the Phase 1 program and Phase 1b/2a CONNECT SCI study in individuals with chronic cervical SCI; and the design and rationale of RESTORE, the Company’s Phase 3 registrational study. Presentations will bring together scientific, clinical and community advocacy perspectives to provide broader context for the program, consider its relevance to the priorities and lived experiences of individuals with chronic cervical SCI, and provide greater detail on RESTORE’s study population and endpoint framework.

NervGen management will be joined by four leading experts whose work spans SCI clinical care, outcome assessment, translational research and community advocacy:

• Benjamin Abramoff, MD, MS — Dr. Abramoff is the Director of SCI Services and Associate Professor of Clinical Physical Medicine and Rehabilitation at the Perelman School of Medicine at the University of Pennsylvania. A board-certified physiatrist in physical medicine and rehabilitation and SCI medicine, he specializes in the clinical care and long-term management of people living with SCI. He also serves on the Pennsylvania Department of Health’s Spinal Cord Research Advisory Committee, where he contributes to recommendations on SCI research priorities.
• Sukhvinder Kalsi-Ryan, PhD, PT — Dr. Kalsi-Ryan led the international development and validation of the Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP), an SCI-specific assessment of upper-limb impairment and function in individuals with traumatic cervical SCI resulting in tetraplegia. A clinician scientist and physical therapist, her research focuses on upper-limb recovery, the measurement of neurological and functional change, and emerging neurorestorative and neuromodulatory approaches following SCI. She is a Clinician Scientist at KITE Research Institute–UHN, an Assistant Professor in the Department of Physical Therapy at the University of Toronto, and Chief Executive Officer and Chief Scientific Officer of Neural Outcomes Consulting.
• Philippa Warren, PhD — Dr. Warren is a Sir Henry Dale Senior Fellow at King’s College London, where she leads the Warren Laboratory within the Wolfson Sensory, Pain and Regeneration Centre. Her group investigates the biological mechanisms that limit motor and respiratory recovery following SCI and therapeutic approaches designed to overcome these barriers. She is the first author of a 2018 Nature Communications study showing that enzymatic degradation of chondroitin sulfate proteoglycans (CSPGs) in a preclinical model restored diaphragm function up to 1.5 years after cervical SCI, and a co-author of The Biology of Regeneration Failure and Success After Spinal Cord Injury (Physiological Reviews, 2018), a widely cited review in the field. Her preclinical research also includes the evaluation of intracellular sigma peptide (ISP; NVG-291-R), the rodent analog of NVG-291, in models of chronic cervical SCI.
• Barry Munro — Mr. Munro is the Chief Development Officer of the Canadian Spinal Research Organization and Director of the North American Spinal Cord Injury Consortium (NASCIC). Since sustaining a spinal cord injury in 1987, Mr. Munro has spent nearly four decades advocating for research that reflects the priorities and perspectives of individuals living with SCI. He has helped advance efforts to establish an SCI-focused Patient-Focused Drug Development (PFDD) meeting, including public discussions on centering the perspectives of individuals living with SCI in drug development. He has also contributed to NASCIC’s SCI Research Advocacy Course, which prepares individuals living with SCI and caregivers to participate as informed partners in research.

The presentations will be followed by a live question-and-answer session.

Webcast Information

To view a live webcast of the event, register here. A recording of the webcast will be available in the "Events & Presentations" section of NervGen’s website at www.nervgen.com.

About NervGen

NervGen (NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic SCI, as observed in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.

Contacts
On365 Partners, Investor Relations
ir@nervgen.com
203.293.8091

David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com
Ignacio.Guerrero-Ros@russopartnersllc.com
858.717.2310

FAQ

What topics will be covered during NervGen's R&D Day on NVG-291?

The R&D Day will review the scientific rationale for NVG-291, nonclinical and translational evidence in spinal cord injury, the drug’s broader therapeutic potential, clinical data from the Phase 1 program and Phase 1b/2a CONNECT SCI study in individuals with chronic cervical SCI, and the design and rationale of RESTORE, the Phase 3 registrational study, including its study population and endpoint framework.

Who are the external experts participating in the NervGen R&D Day?

Four experts will join NervGen management: Dr. Benjamin Abramoff, Director of SCI Services at the Perelman School of Medicine at the University of Pennsylvania; Dr. Sukhvinder Kalsi-Ryan, clinician scientist and physical therapist known for developing the GRASSP assessment and affiliated with KITE Research Institute–UHN and the University of Toronto; Dr. Philippa Warren, Sir Henry Dale Senior Fellow at King’s College London leading the Warren Laboratory on motor and respiratory recovery after SCI; and Barry Munro, Chief Development Officer of the Canadian Spinal Research Organization and Director of the North American Spinal Cord Injury Consortium.

How can investors and other participants access the NervGen R&D Day?

The event will be available via a live webcast on Wednesday, September 30, 2026, starting at 10:00 a.m. ET. To view the live webcast, participants must register using the provided registration link. A recording of the webcast will later be available in the “Events & Presentations” section of NervGen’s website at www.nervgen.com.

What perspectives beyond clinical data will be highlighted at the R&D Day?

Presentations will incorporate scientific, clinical and community advocacy perspectives. The company said the event will consider the relevance of NVG-291 and the RESTORE study to the priorities and lived experiences of individuals with chronic cervical SCI, supported by expert input in outcome assessment, translational research and patient advocacy.